Exosome Therapy: Evidence, Safety and Vietnam Clinics

What exosomes are

An exosome is an extracellular vesicle, a tiny bubble released by cells, and it is neither a cell nor a peptide. Vietnamese medical press describes it as tui ngoai bao, literally an extracellular vesicle, that originates from cells in the body and is found in fluids such as plasma, saliva, and tears.¹⁷ Inside its lipid membrane it carries cargo: growth factors along with genetic material such as DNA, mRNA, and microRNA.¹⁷ It is explicitly not a cell, it acts as a carrier with properties similar to those of stem cells.¹⁷ A Vietnamese commercial provider puts the size at 30 to 150 nanometers,²¹ and one human study measured the particles at about 139.7 nanometers, plus or minus 2.3, by nanoparticle tracking.³

Because an exosome is a package rather than a single active drug, exosome therapy is not one treatment. What a product does depends on the cell the exosomes were harvested from and what those exosomes carry, a point that runs through everything below. In the United States, the FDA treats exosomes used to treat disease as drugs and biological products subject to approval, and it states there are currently no approved exosome products.¹ How the evidence and the marketing can diverge for another injectable category is the subject of the HGH versus peptides guide.

What the human evidence shows

Human evidence for exosome therapy is thin, recent, and mostly low grade. The studies gathered for this guide cluster in a few areas: hair loss, facial skin, knee osteoarthritis, and COVID-19 pneumonia. Almost all are small, several have no control group at all, and the largest count anywhere in this evidence was 39 patients, in a single clinical study counted by a 2023 systematic review.⁵ Two hair studies were followed by reported gains in hair density, one after scalp injection in 30 men, with a statistically significant increase at weeks 4 and 12 and no side effects noted,³ and one after topical application over microneedling in 16 men, with a mean gain of 35 hairs per square centimeter at 12 months.⁴ Both carried a Level IV evidence grade assigned by the journal, a low tier, and both were uncontrolled.

Beyond hair, a randomized ascending-dose trial in knee osteoarthritis reported that treatment did not cause any adverse consequences and found a certain degree of effectiveness in clinical scores and MRI, language that is careful for a reason.⁶ A split-face facial-skin trial found topical exosomes equal to platelet-rich plasma, or PRP, on wrinkles, tone, and texture, but the comparison was against PRP, not against placebo or no treatment.⁷ A nebulized pilot in seven patients with COVID-19 pneumonia reported no acute allergic reactions.⁸ The single most important number across all of it is the one that is missing.

None of the human study abstracts gathered here stated the dose that was given. That does not mean no dose was used, only that the abstracts do not report one, so this guide cannot state a human dose and does not. A 2023 systematic review of exosomes in hair restoration captured the state of the field: 16 studies, of which 15 were preclinical and only 1 was clinical, with the review reporting no significant adverse reactions so far while still calling for further work to address safety concerns.⁵

Animal studies, in both directions

Most exosome research still sits in animals, and it cuts two ways at once. On one side, a mouse study of an engineered exosome that carried a microRNA cluster reported giving 100 micrograms intravenously once a week for 8 weeks (animal study, db/db mice, intravenous, PMID 37596398).⁹ That is the only complete dose, route, and schedule anywhere in the studies gathered for this guide, and it describes a laboratory construct rather than any product a clinic sells. Other animal work used human umbilical cord exosomes by tail vein in rats, with the dose not stated in the abstract,¹⁰ and human skin fibroblast exosomes delivered by a needle-free injector in a photoaging mouse model, again with the dose not stated in the abstract.¹¹

That second list is the direction marketing rarely mentions. In each of those studies, injecting exosomes into animals caused harm rather than benefit,^1213141516 because an exosome is a delivery vehicle whose effect depends entirely on the cell it came from and the cargo it carries. This is the strongest reason not to treat exosome as a single product with a single safety profile. The word names a category of particle, not one defined medicine, and the source cell matters more than the label on the vial.

Safety and the FDA position

The reassuring safety signals come from small, mostly uncontrolled studies: no side effects reported in the 30-patient hair study,³ mild scalp soreness that resolved within 48 hours in the 16-patient hair study,⁴ no acute allergic reactions in the 7-patient nebulization pilot,⁸ and no adverse consequences in the knee osteoarthritis trial.⁶ The 2023 hair-restoration review likewise reported no significant adverse reactions so far, while explicitly asking for more work on safety.⁵ Small and uncontrolled is the key qualifier: none of these was large enough or controlled enough to detect a rare or delayed harm.

Against that sits the clearest safety signal on the record, and it comes from a regulator. In 2019 the US FDA issued a public safety notification about multiple reports of serious adverse events in patients in Nebraska who were treated with unapproved products marketed as containing exosomes.¹ The notification names the CDC and the Nebraska Department of Health and Human Services but states no patient count, no organism, no product name, and no clinic, so this guide does not supply those details either. The agency states plainly that there are no FDA-approved exosome products and that exosomes used to treat disease are regulated as drugs and biological products.¹ A separate FDA consumer alert lists conditions for which no stem cell or exosome product has been approved, including orthopedic, neurological, cardiovascular, and pulmonary uses.²

Exosome therapy in Vietnam

In Vietnam, the published position is easier to state than to verify. A 2023 article in the newspaper Tien Phong reports that exosome is licensed in Vietnam as a cosmetic, my pham, and not as a drug, thuoc, and that it may therefore be used only for topical application, boi thoa, and not for injection.¹⁷ That is the clearest Vietnamese-language statement of the licensing position found within this research, but it comes with a caveat the reader deserves: the article closes with a promotion for a named clinic, which makes it branded content rather than independent reporting, and the claim could not be confirmed against the Drug Administration of Vietnam registration database, whose search results were not machine-readable when the portal was queried.²² Treat it as a reported claim, not as the words of a regulator.

The surrounding climate is stricter than the cosmetic framing suggests. In August 2026 the Hanoi Department of Health issued document 8015/SYT-NVY warning that the Ministry of Health has not licensed any facility in Vietnam to provide human stem cell beauty products as advertised, and that Hanoi has approved no facility for stem cell procedures in medical care.¹⁸ Two independent outlets reported the same notice.¹⁹ One precision matters here: that document addresses stem cells, te bao goc, along with NMN and NAD+ infusions, and it does not use the word exosome. An exosome is not a stem cell, so this notice describes the regulatory weather around exosome clinics rather than a ruling on exosomes themselves.

On the retail side, the largest pharmacy chain in Vietnam, Long Chau, listed no product at all under the keyword exosome when its own on-site search was run in September 2026, a genuine empty result rather than a blocked page.²⁰ Where exosome therapy is sold, it is sold through clinics and specialist providers. One provider published price list, dated July 2025, gives a sense of the range.

The same list quotes Singapore-sourced product higher, at 12 to 18 million VND per session, and sells joint injections and IV infusions as courses of 3 to 5 sessions.²¹ These are the figures of one commercial site, not a market average, and prices elsewhere may differ. Another regenerative therapy sold through Vietnamese clinics and IV drips, with its own regulatory questions, is covered in the NAD+ therapy in Vietnam guide.

The short version

Sources and references

Every figure on this page traces to one of the sources below. PubMed entries are cited by PMID, and each quotation was taken from the study abstract or the regulator page named. Where a fact could not be verified within the research, the page says so rather than filling the gap.